Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Page 1
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Marvin-Peek J, et al. Among authors: wang sa. Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38749022
We report on the long-term efficacy and safety of a phase 2 trial of sequential cladribine and rituximab in hairy cell leukemia (HCL). ...
We report on the long-term efficacy and safety of a phase 2 trial of sequential cladribine and rituximab in hairy cell leukemia (HCL) …
Supervised machine learning algorithms to predict the duration and risk of long-term hospitalization in HIV-infected individuals: a retrospective study.
Li J, Hao Y, Liu Y, Wu L, Liang H, Ni L, Wang F, Wang S, Duan Y, Xu Q, Xiao J, Yang D, Gao G, Ding Y, Gao C, Xiao J, Zhao H. Li J, et al. Among authors: wang s. Front Public Health. 2024 Jan 5;11:1282324. doi: 10.3389/fpubh.2023.1282324. eCollection 2023. Front Public Health. 2024. PMID: 38249414 Free PMC article.
Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report.
Mu X, Duan Y, Xu Q, Wang S, Gao G, Han N, Zhao H. Mu X, et al. Among authors: wang s. Front Pharmacol. 2023 Oct 31;14:1268597. doi: 10.3389/fphar.2023.1268597. eCollection 2023. Front Pharmacol. 2023. PMID: 38027007 Free PMC article.
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential toxicity and drug interactions of long-term antiretroviral therapies. We describe a female patient with HIV, who was admitted to the e …
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential t …
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Kadia TM, et al. Among authors: wang s. Am J Hematol. 2023 Nov;98(11):1711-1720. doi: 10.1002/ajh.27054. Epub 2023 Aug 27. Am J Hematol. 2023. PMID: 37635400 Clinical Trial.
The addition of sorafenib to CLIA in FLT3-ITD mutated AML resulted in high rates of durable remission and excellent long-term survival....
The addition of sorafenib to CLIA in FLT3-ITD mutated AML resulted in high rates of durable remission and excellent long-term surviva …
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Jabbour E, et al. Among authors: wang sa. Lancet Haematol. 2023 Jun;10(6):e433-e444. doi: 10.1016/S2352-3026(23)00073-X. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187201 Clinical Trial.
BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse disease biology and their inability to tolerate intensive therapy. We aimed to study the long-term outcomes of inotuzumab ozogamicin …
BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse …
One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C.
Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. Xu JH, et al. Among authors: wang s. World J Clin Cases. 2022 Oct 6;10(28):10085-10096. doi: 10.12998/wjcc.v10.i28.10085. World J Clin Cases. 2022. PMID: 36246814 Free PMC article. Clinical Trial.
Two HBeAg-positive patients in Group A and 5 in Group B developed genotypic resistance to ETV. CONCLUSION: Long-term ETV maleate treatment for up to 192 wk is effective and safe in Chinese CHB patients predominantly genotyped as B or C....
Two HBeAg-positive patients in Group A and 5 in Group B developed genotypic resistance to ETV. CONCLUSION: Long-term ETV maleate trea …
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. Short NJ, et al. Among authors: wang s. Blood Adv. 2022 Jul 12;6(13):4006-4014. doi: 10.1182/bloodadvances.2022007378. Blood Adv. 2022. PMID: 35533262 Free PMC article.
Early assessment of MRD using a highly sensitive NGS assay adds clinically relevant prognostic information to standard MFC-based approaches and can identify patients with ALL undergoing frontline therapy who have a very low risk of relapse and excellent long-term survival. …
Early assessment of MRD using a highly sensitive NGS assay adds clinically relevant prognostic information to standard MFC-based approaches …
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Tanaka T, et al. Among authors: wang sa. Blood. 2021 Nov 4;138(18):1733-1739. doi: 10.1182/blood.2020010483. Blood. 2021. PMID: 34115096 Free PMC article.
Although clonal hematopoiesis (CH) can precede the development of acute myeloid leukemia (AML), it can also persist after achieving remission. Long-term clonal dynamics and clinical implications of persistent CH are not well understood. ...Postremission CH was identified i …
Although clonal hematopoiesis (CH) can precede the development of acute myeloid leukemia (AML), it can also persist after achieving remissio …
The prognostic implications of perioperative endogenous hydrogen sulfide and nitric oxide levels in children with congenital heart disease complicated by pulmonary arterial hypertension.
Tan Y, Wang S, Ren X, Zhang C, Xu F. Tan Y, et al. Among authors: wang s. Eur J Pediatr. 2021 Jun;180(6):1915-1922. doi: 10.1007/s00431-020-03897-w. Epub 2021 Feb 8. Eur J Pediatr. 2021. PMID: 33555425
What is New: This study was designed to explore the relationship between short-term prognostic indexes and hydrogen sulfide and nitric oxide levels, in an effort to provide a frame of reference for the postoperative monitoring and treatment of children with congenital hear …
What is New: This study was designed to explore the relationship between short-term prognostic indexes and hydrogen sulfide and nitri …
23 results